Piper Sandler Maintains Neutral on Silk Road Medical, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder maintains a Neutral rating on Silk Road Medical (NASDAQ:SILK) and raises the price target from $11 to $18.
February 29, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on Silk Road Medical but raises the price target from $11 to $18.
The increase in the price target from $11 to $18 by Piper Sandler suggests a positive outlook on Silk Road Medical's stock value in the short term, despite maintaining a Neutral rating. This adjustment in the price target could lead to increased investor interest and potentially a rise in the stock price as the market adjusts to the new valuation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100